In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the ...

The research is a transformative step toward understanding the condition's genetic underpinnings and potential for ...

Shorter-form messaging seems to be preferable for recruiting participants to enroll in clinical trials, according to a research letter published online June 25 in the Journal of the American Medical ...

TPU researchers, together with their Russian and foreign colleagues, have developed a technology that makes it possible to ...

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.

S, the best course of action is to correct the energy imbalance by managing nutrition and training, and in these cases, meds ...

When blockbuster drugs lose IP protections it can wipe out billions of dollars in revenue for companies ...

An antidiabetic mainstay did not provide an additional survival benefit to patients with metastatic hormone-sensitive prostate cancer, according to results from a phase ... showed a difference in ...